China Biopharma (01177.HK) said it has deepened its strategic cooperation with
GlaxoSmithKline (GSK.N). Under the expanded agreement, subsidiary Zhengda
Tianqing will manage importation, distribution, hospital access and promotion in
mainland China for two GSK respiratory products: fluticasone furoate inhalation
powder and umeclidinium bromide/vilanterol inhalation powder. The parties had
earlier reached a collaboration on bringing innovative hepatology drugs to
market in China.
